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Chemical imaging provides new insight into the fundamental atomic, molecular, and biochemical
composition of tissue and how they are interrelated in normal physiology. Visualising and quantifying
products of pathogenic reactions long before structural changes become apparent also adds a new
dimension to understanding disease pathogenesis. While chemical imaging in isolation is somewhat
limited by the nature of information it can provide (e.g. peptides, metals, lipids, or functional groups),
integrating immunohistochemistry allows simultaneous, targeted imaging of biomolecules while also
mapping tissue composition. Together, this approach can provide invaluable information on the inner
workings of the cell and the molecular basis of diseases.
Key learning points
(1) Chemical imaging must be redefined to encompass all analytical techniques that can spatially map the chemical composition of a sample.
(2) Immunohistochemistry has many applications in chemical imaging, from co-localising individual proteins with chemical components to multiplexed
experiments for profiling biochemical pathways and cell hierarchies.
(3) The significance of an immunohistochemistry and chemical imaging approach is not necessarily based in technology, but how it is applied to answer a
primary research question.
(4) Immunostaining may inadvertently perturb the native biochemistry of the system being imaged, and the effects of each potentially confounding step should
be considered when validating a method.
(5) Combining immunohistochemistry with novel applications of chemical imaging presents new opportunities and technical challenges that should be
considered research priorities to allow further growth in the field.
1. Introduction
The complexity of a biological system is reflected by the
dynamic microchemical environment found within cells and
tissues. Imaging technology has advanced to a point where
specific biochemicals can be targeted and visualised, poten-
tially in real time. Traditional anatomical pathology, for which
visualising microstructure was once the primary outcome, has
greatly benefited from advances in analytical technology and
their application to chemical imaging. Biologists now have a
range of chemical imaging tools at their disposal that comple-
ment, and in some cases even supplant, conventional methods
for spatially profiling the structure and biochemical makeup of
cells, organs, and even whole organisms.
Histology and histochemistry are the standard approaches for
visually assessing gross tissue morphology, cell type, subcellular
structure, and the presence of endogenous chemicals that react to
form coloured compounds with certain dyes and stains. While
having an important place in both analytical biochemistry and
diagnostics, these methods are primarily qualitative and have
limited specificity at the molecular level. Many chemical compo-
nents of biological systems fall outside the scope of traditional
histochemistry and have necessitated the development of alterna-
tive approaches to reconstruct their spatial distribution. Simply
identifying a biomolecule presents only a partial picture; visualising
spatial distribution and associating it with structural or other
biochemical features is crucial to fully understand involvement in
a defined biological mechanism or relevance to disease.
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In the latter case, changes to the chemical properties and
compartmentalisation of one or more disease-associated species
often precede the appearance of cytopathology. Pathology may
manifest from altered concentrations or chemical modifications
that impart toxicity either independently or via aberrant inter-
actions with other biological components, though simple redistri-
bution of a biochemical without overt changes to chemical state
or structure can also precipitate systemic dysfunction. Identifying
when, and most importantly where, normal physiological condi-
tions are disturbed is crucial for elucidating the molecular basis of
disease. Accurately measuring the degree of change and where it
occurs opens new avenues of investigation for targeted therapies
and biomarker discovery.
The use of antibody labelling with a chemical marker was
first described with fluorescent b-anthryl-carbamide conju-
gated to anti-pneumococcus in 1941.1 Biomolecules that were
previously undetectable using histochemical staining and light
microscopy suddenly became ‘visible’. Three-quarters of a
century later, novel uses of technology (some by design, others
through creative repurposing) and innovations across all sub-
disciplines of chemistry have made available a diverse chemical
imaging toolbox, spanning whole organs to single molecules
and atoms.
Immunohistochemistry (IHC) has now become routine,
although experimental protocols, reagents, detection techni-
ques, and image analysis methods are constantly extending
upon what information can be extracted. However, aside from a
handful of clinically-approved protocols and the gradual uptake
of automation outside high-throughput laboratories, it is also a
somewhat imprecise science. Sample preparation requires sub-
stantial handling, chemical treatment and, when developing
new assays, a degree of trial-and-error. When properly executed,
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contemporary IHC is enormously powerful for analytical bio-
chemistry; be it as a cell-specific marker for cytometry or probe
sensitive only to the subtlest disease-associated chemical
change occurring from single point genetic mutations. Coupling
IHC with chemical imaging, in all its forms, expands the scope
even further—now direct associations between antibody targets
and other biological components can be made in single-origin
samples. That being said, integrating IHC with chemical imaging
is not trivial—considerable planning and preparation, paired
with a good understanding of the fundamental principles that
underpin both IHC and chemical imaging as separate disciplines
is a necessity.
In this Tutorial Review we provide a guide for designing IHC
imaging experiments that capitalise on the latest developments
in chemical imaging using analytical spectroscopy and mass
spectrometry. Integrated IHC and chemical imaging as a
research tool falls into two categories with substantial overlap
in terms of possible applications: (i) routine IHC protocols are
applied in sequence or in parallel with chemical imaging for
interrogating spatial associations and relationships between
labelled antibodies and endogenous chemicals; and (ii) novel
applications of IHC with diverse and exotic chemical reporters
that extend beyond the capabilities of routine methods. We
summarise the imaging technology available with a focus on the
abilities and shortcomings intrinsic to each. We then discuss
where sample preparation steps both align with and deviate
from standard conventions for IHC, and how the necessary steps
to prepare samples for IHC may impact endogenous chemicals
of interest. Using the lessons learned from traditional IHC and
the common chemical imaging methods employed, we outline
how future validation studies should be designed for potential
clinical translation. Finally, we examine a selection of novel
examples of IHC-chemical imaging, highlighting the achieve-
ments that have been made, outline how specific research
questions are driving method development, and speculate on
where the future potential of IHC-chemical imaging lies.
2. Redefining chemical imaging
The current definition of chemical imaging describes the use of
spectroscopy to measure unique interactions between photons
and matter in two, three, and occasionally four dimensions,
though the emergence of imaging mass spectrometry (MS) in
recent years justifies extension to include direct spatial profiling
of chemical composition. This expanded definition shifts the
focus to the shared ability of spectroscopy and spectrometry to
collect multiple spectra reflecting specific chemical features pre-
sent in a defined area, and to use this information to construct
spatial measures of chemical distribution. This broader descrip-
tion of chemical imaging, when used in sequence and combined
with IHC, emphasises that nearly every class of biomolecule is
amenable to spatial analysis at resolutions extending from the
mesoscale into the subcellular domain, depending on the method
used. Rather than present an in-depth discussion of technologies
available, we have summarised key features and considerations
in the context of IHC-chemical imaging in Table 1 and direct
the reader to key technical reviews and texts.
In most cases, combining IHC and chemical imaging does
not necessarily supersede histochemistry; rather, it offers
an opportunity to gather more detailed information about the
presence, quantity, and chemical state of specific biomolecules.
Each chemical imaging technique normally excels at one parti-
cular task, such as how Fourier-transform infrared (FTIR) and
Raman spectroscopy can plot spectroscopic qualities of the
predominant chemical environment while mass spectrometry
imaging (MSI) uses a more targeted approach to isolate and
map specific chemicals by mass. While investigation of a specific
target may be optimally achieved with single imaging technique,
the true power is in spatial profiling of multiple chemicals and
using this data to decipher the complex interplay occurring
between them. The utility of chemical imaging in biology is
further enhanced by the capacity to simultaneously measure
and spatially associate biomolecules identified with exogenous
tags and unlabelled chemical species.
3. A beginner’s guide to
immunohistochemistry for chemical
imaging
Antibodies are glycoproteins with a specific affinity to a portion
of a target biomolecule, known as an antigen. The antigen-
binding site, or paratope, of an antibody is sensitive to the
epitope of the antigen, which may be as small as a specific
amino acid sequence (linear epitopes) or as large as part of the
antigen tertiary structure (conformational epitopes). Antibodies
are part of an organism’s innate immune response and can be
produced with specificity for nearly all biomolecules, including
misfolded or mutated variants involved in specific disease states.
However, even the most robustly-validated and clinical-approved
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Table 1 Summary of main technical features, capabilities and limitations of chemical imaging techniques compatible with IHC (charge-coupled device,
CCD; focal plane array, FPA; Fourier-transform infrared, FTIR; laser ablation-inductively coupled plasma-mass spectrometry, LA-ICP-MS; laser induced
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IHC assays are prone to analytical error and interference, and the
number of research-only applications dwarfs those that have
been approved for clinical use. Prior to explicit guidelines for
IHC analytical validation issued by the US College of American
Pathologists (CAP) Pathology and Laboratory Quality Center in
2014 (discussed in detail in Section 3.4),11 clinical pathology
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laboratories had no set instructions to follow, and instead
either replicated prior examples of validated and Food and
Drug Administration (FDA)-approved predictive immunoassays
(such as the oncogene-product human epidermal growth factor
2 [HER2]), or developed internal method validation protocols.
Considering that IHC-chemical imaging is still in relative
infancy, now is a critical time to establish consensus-driven guide-
lines for method development and eventual clinical translation.
Instituting such standards cannot be the responsibility of one
laboratory or research group, though we can identify key consid-
erations in designing chemical imaging experiments that employ
antigen-specific detection for both immediate research use, and as
parameters for future multi-site concordance studies. It is also
important to recognise that, in a rapidly growing field, new con-
founding factors are constantly being identified, and designing
future experiments should encompass these as they are reported.
At this point it is also important to make a clear distinction
in the nomenclature used throughout this Tutorial Review:
when referring to an analyte, we are describing the species that
is directly detected using chemical imaging, whereas antigen is
used to describe the associated biomolecule (Fig. 1).
The class of analyte suitable for IHC-chemical imaging is
limited only by what can form a stable and specific association
with either the primary or secondary antibody. Traditional IHC
relies on spectroscopic properties of the analyte, such as propen-
sity to form a coloured precipitate with specific stains or fluoresce
when excited. Manipulating photon–matter interactions and
improving how they are detected drives development of new
technology. Fluorescence microscopy can therefore be considered
as both routine—it is one of the most widely used laboratory
techniques in the world—and intersecting the cutting-edge of
physics, chemistry and biology. Recent technical advances, such
as overcoming the light diffraction limit to allow super-resolution
microscopy certainly offer unique opportunities, though ‘routine’
fluorescence microscopy is still central to many IHC-chemical
imaging applications. This highlights a key learning point: the
significance of an imaging approach is not necessarily based in
technology, but how it is applied to answer a primary research
question. The development of a new analyte, its integration into
an existing IHC protocol, and use in aiding visualisation of the
surrounding microchemical environment is as important as
emergence of new imaging techniques. In this Tutorial Review,
we focus on selecting (or developing) the analyte rather than
imaging technique, acknowledging that certain analyte classes
are applicable to multiple analytical methods.
As most protocols involve labelling an antibody with an
analyte prior to incubation with a sample, standard protocols
for IHC are generally applicable. Depending on the analyte, an
IHC-chemical imaging experiment may use primary antibodies
pre-labelled with a chemical reporter, or apply labelled secondary
antibodies as an amplification step (Fig. 2). Both approaches have
intrinsic advantages and limitations related to the choice of
analyte and imaging technique. In this section, we provide a guide
to developing an IHC-chemical imaging experiment, emphasising
the importance of good experimental design based on the
principles of analytical method validation.
3.1 Designing an IHC-chemical imaging experiment
The first question an analyst should ask when embarking on
experiments that integrate IHC with chemical imaging is: can the
intended outcome provide information not currently achievable
with existing protocols and technology? Developing a method
Fig. 1 Schematic of antigen–antibody binding for detecting biomolecules.
(a) Antibodies are large glycoprotein immunoglobulins with a ‘Y’-shaped
monomeric structure. The two B50 kDa heavy chains consists of three
constant domains (CH1–3) and a N-terminus variable domain (VH) that forms
one half of the antigen-binding site. The two light chains (B25 kDa) contain
a constant domain (CL) at the C-terminus and a corresponding variable
domain (VL) to complete the antigen-binding paratope. Interchain disulfide
bonds link the heavy and light chains within the constant domains, with two
additional disulfide bridges at the hinge region between CH1 and CH2. The
Fab region contains the paratope, whereas the Fc region is the site of
secondary antibody binding. (b) Primary antibodies recognise specific amino
acid sequences or structural features of the antigen, referred to as the
epitope, at 1 : 1 stoichiometry. Signal amplification is typically achieved by
secondary antibodies labelled with a fluorophore or chromogen, though
metal tags have specific applications. Multiple binding sites in the Fc region
increases the number of chemical analytes that can be associated with a
single antigen (see Fig. 2).
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using a novel chemical analyte that produces a similar result to
that which could be obtained using traditional methods may be
of interest to a subset of researchers, though its potential impact
within the wider field of anatomical pathology will be limited.
Fig. 2 Antibodies and analytes for IHC-chemical imaging. (a) Primary (11) antibodies provide the highest specificity and greatest potential for
multiplexing using unique chemical reporters (such as isotopically-enriched lanthanides); (b), though have lower sensitivity. (c) Secondary (21) antibodies
raised against the primary host organism are therefore used to amplify signal and improve detection limits, coming with their own limitations. (d) Light
microscopy employs chromogens, normally linked to the 21 IgG via a biotin–streptavidin complex with a peroxidase (shown here as horseradish
peroxidase, or HRP) substrate for 3,30-diaminobenzadine (DAB) oxidation. Addition of divalent metal ions (e.g. Ni2+, Co2+) forms a darker precipitate, and
while these could be used as a proxy for imaging by LA-ICP-MS, caution should be taken due to potential interference from physiological sources.
(e) Fluorophores use an excitation source to induce emission of Stokes-shifted photons with brightness proportional to the product of the fluorophore
quantum yield (ff) and extinction coefficient. Quantum dots are photon-emitting nanomaterials with cores comprised of group II–VI, group III–V,
or group IV–VI binary compounds and zinc sulfide shells that produce stable, bright, and narrow emission spectra which can be tuned by manipulating
particle size. Quantum dots can be conjugated to antibodies via several methods, most commonly using –COOH, –NH2 and –SH functional groups on
the particle surface to crosslink with amino acids. In addition to superior ff, near-infrared properties of quantum dots can be exploited with IR imaging,
and the exogenous metal/metalloid composition with atomic spectrometry. (f) Gold and silver nanoparticles (Au/Ag NP) are particularly useful in MS
imaging for amplifying signal attributable to low-abundance antigens, or as a substrate for SERS; while MeCATs use 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) macrocycles to chelate lanthanide ions, including radionuclides. (g) Addition of prosthetic reactive groups permits
selective binding of the DOTA chelate to specific amino acid residues on the IgG carrier (isothiocyanate, SCN; N-hydroxysuccinimide, NHS; maleimide,
Mel; iodoacetamide, IA). (h) Photocleavable tags are also used in MS imaging, and typically consist of a peptide of known mass and structure linked to a
photosensitive moiety and biotin–avidin complex, represented here with an avidin-coated glass bead.
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Where it is clear that traditional IHC approaches are insuffi-
cient to answer the question at hand and that chemical imaging
offers capabilities that overcome such limitations, the next step is
to identify what properties of the sample in question are subject to
analysis. These include, but are not limited to, quantifying the
amount of endogenous chemicals present, spatial assessment of
how multiple antigens and biochemicals interact, high-resolution
imaging of subcellular compartmentalisation, or even providing
complementary information for traditional IHC methods. Here
we provide here a guide based on known quantities that various
chemical imaging methods can inform. The reader should not
consider this list exhaustive as the discipline is rapidly evolving,
and the emergence of new technologies will see the scope of
IHC-chemical imaging broaden.
3.1.1 Analytical sensitivity. Use of the terms sensitivity (the
smallest amount of analyte detectable) and specificity (the con-
fidence that the measured signal is representative of only the
analyte) in an analytical context should not be confused with
diagnostic sensitivity and specificity of IHC, which refers to the
ability of an assay to reliably detect a specific disease-associated
antigen. As such, a scenario can exist where an IHC assay has high
diagnostic sensitivity and specificity while the antigen in question
is present at high levels, and only in a certain disease state.
Immunohistochemical detection of an antigen can be divided
into two categories: (i) direct detection, where the primary antibody
is conjugated to a suitable analyte in the Fc domain; or (ii) indirect
detection, where an immunoglobulin (typically IgG) raised against
the primary host species (e.g. rabbit anti-mouse IgG for a murine-
derived primary antibody) with a conjugated analyte is introduced.
Direct detection requires fewer sample processing steps and has a
high capacity for multiplexing by eliminating species cross-
reactivity of secondary antibodies, though in the majority of cases
antibody-to-antigen stoichiometry is 1 : 1 which can limit sensitivity
relative to indirect detection. The signal intensity attributable
to the analyte is proportional to its concentration—which is
technically an indirect measure of total antigen recognition by
the primary antibody, though we use terms specific to IHC
protocols in this Tutorial Review—and as multiple secondary
antibodies can bind to the Fc region of a primary immuno-
globulin, signal amplification is achieved by increasing the
number of analytes associated with a single antigen.
Sensitivity is also determined by the detection technique.
Spectroscopic chemical imaging requires the ability to detect and
spatially resolve subtle changes in energy resulting from inter-
actions between photons and matter, while mass spectrometry-
based imaging depends on efficient physical transfer, separation,
and detection of material directly removed from the sample
surface. For a technique such as matrix assisted laser desorption/
ionisation (MALDI) MS, this can be as little as 1–10 attomoles
of total material per pulse (depending on laser and matrix
conditions),12 within which the total analyte may be present
at levels several orders of magnitude lower.
The amount of detectable signal that can be attributed to a
defined area determines both the sensitivity and achievable
spatial resolution (see Section 3.1.3) of an imaging technique.
Technical limits such as focal point, laser pulse diameter and
the dynamic range of the detector are nominally fixed, making
control of variables in sample preparation and IHC protocols
the major determinant of analytical sensitivity. A successful
IHC protocol applied to chemical imaging should demonstrate
reproducible measurements of analyte areal density with high
signal-to-noise.
Equal attention should also be given to the practical detection
limits for endogenous chemicals of interest. Factors to consider
include whether the dynamic range of the detector is compatible
with the different concentration ranges of the analytes and
associated biochemicals, if further chemical derivatisation is
necessary, and whether an additional mode of detection should
be used in sequence. It is not uncommon for individual factors
affecting sensitivity of either the analyte or endogenous chemi-
cals to impose a compromise in imaging parameters used.
3.1.2 Antibody specificity. Specificity refers to the ability of
the primary antibody to bind exclusively to the epitope of the
antigen against which it was raised. Monoclonal antibodies are
more specific than polyclonal variants as they recognise a single
epitope on an individual antigen with the same affinity (known
as monovalence). The trade-off is that they are more expensive
to produce and are less sensitive, requiring substantial signal
amplification for most detection techniques. Polyclonal anti-
bodies recognise several epitopes on one or more antigens with
differing degrees of affinity (polyvalence). The increased binding
enhances sensitivity, though variable antibody–antigen stoichio-
metry and non-specific binding to equivalent epitope structures
in other biomolecules introduces a degree of ambiguity for
experiments where relative comparisons are made. Specificity
is further complicated by inconsistencies in binding efficiencies
between suppliers and the clones used to produce antibodies,
and this is an important factor to consider when validating an
IHC-chemical imaging protocol (see Section 3.3).
3.1.3 Image resolution. Fluorescence microscopy by far
offers the highest practical spatial resolution, and the break-
through of the 200 nm diffraction limit achieved by super resolu-
tion microscopy allows images approaching the low nanometre
scale. Contemporary electron and scanning-probe microscopy
systems are capable of resolving structural features in the pico-
metre range, though it could be argued that imaging antibody–
antigen complexes at such a resolution exceeds the requirements
of most IHC experiments—atomic force microscopy was used to
determine that a single antibody is approximately 20 nm in
diameter.13 Particle and X-ray-induce atomic emission spectro-
scopy are capable of producing sub-micron resolution images,
and simultaneously spatially profile physical properties of a
sample that can be related to cell structures.
With the exception of secondary-ion mass spectrometry
(SIMS), MS imaging techniques are typically limited to meso-
scale (41 mm) resolution. This is primarily due to the same
determinants of sensitivity, and resolution will improve as MS
technology does.
3.2 Developing an IHC-chemical imaging experiment
The next question to be addressed when designing an experi-
ment is: how can the desired outcome be met? This requires an


























































































3778 | Chem. Soc. Rev., 2018, 47, 3770--3787 This journal is©The Royal Society of Chemistry 2018
understanding of the variables that influence analytical validity
and knowledge of the strengths and limitations of the imaging
technique used. There is no universal protocol or checklist to
follow for integrating IHC with chemical imaging—antibodies
and biological systems are a far cry from the standard reference
materials an analytical chemist would typically use to develop
and validate a new method. Acknowledging that combined IHC
and chemical imaging is an emerging field where potential
measures and experimental outcomes are still being actively
developed, we provide a general guide that can be adapted to
suit the experiment to be performed.
3.2.1 Considerations when preparing samples for IHC.
Biological samples are a heterogeneous mixture of elements,
inorganic and organic small molecules, peptides, proteins,
nucleic acids, lipids, and carbohydrates. Cell structures have
unique chemical environments resulting from how these com-
ponents are structurally arranged and their relative concen-
trations. Any IHC experiment requires some form of sample
pre-treatment. Fixation preserves cell structure and immobilises
biomolecules—a sample will degrade if metabolic processes
continue ex vivo. Antigen retrieval is often needed to ‘undo’ the
chemical and physical modifications that fix proteins in place.
Permeabilising cell membranes opens cellular compartments to
large immunoglobulins while also allowing labile species to
diffuse out. Long-term storage requires complete dehydration
and infiltration with paraffin to retain cell morphology.
Each step exerts some influence on the microchemical
environment, dependent on preparation method and the class
of chemical affected (Fig. 3). A true depiction of an undisturbed
biological system is inherently unobtainable; even live-cell imaging
is subject to an ‘observer effect’, a concept that acknowledges
chemical alterations can result from the imaging technique
itself.14 As such, there is no ‘standard’ of a completely undisturbed
system against which an image can be compared, and the few
studies that have specifically measured chemical alterations result-
ing from sample preparation indicate the effects are wide-ranging
and cover every class of biochemical. When developing an IHC
protocol intended to assess spatial relationships between
antibody-bound antigens and native species, the aim should
be to both minimise ex vivo perturbations to natural chemical
distribution and, while recognising that some degree of modi-
fication is unavoidable, ensure all samples undergo identical
preparation procedures.
Cryofixation is the least damaging form of sample preserva-
tion and is the preferred method for the majority of chemical
imaging techniques, though it is also the most technically
challenging. Rapid uniform cryogenic freezing vitrifies a sample,
transforming liquid H2O into molecularly-disordered amorphous
ice. By preventing H2O molecules from assembling into a hexa-
gonal lattice structure, damage to cell morphology resulting
from ice crystal growth is minimised. Cryoprotectants including
polyethylene glycol and disaccharides can also be added to
reduce crystal formation. Water is then removed by either
addition of cooled organic solvents (freeze-substitution) or sub-
limation via low pressure lyophilisation, after which IHC can be
performed on resin-embedded sections at standard laboratory
conditions. Optimal cryofixation methods vary depending on
sample type, and detailed protocols can be found in the book by
Wolkers and Oldenhorf.15 Excellent preservation of cell ultra-
structure makes cryofixation particularly attractive for electron
microscopy, and subsequent immunostaining with gold–
nanoparticle conjugated antibodies has been used to demonstrate
superior labelling efficiency of insoluble proteins compared to
chemically-fixed samples.16 Rapid freezing of whole tissue
samples followed by cryosectioning and chemical fixation of
cut tissue is an alternative approach for imaging techniques
Fig. 3 Sample processing steps for IHC and associated effects on native
cell biochemistry. (a) The aim of cryofixation is to cool the cell at a rate that
prevents H2O molecules forming an ordered crystalline structure in favour
of an amorphous glass-like disordered arrangement of supercooled H2O
molecules that retains mechanical properties of a liquid. If the rate of
cooling is too slow spontaneous nucleation and growth of ice crystals can
rupture membranes, damaging cellular microstructures and causing both
intra- (e.g. release of immature proteins from inside ribosomes on rough
endoplasmic reticulum into the cytoplasm) and intercellular (e.g. interstitial
exchange of molecules and ions through ruptured cell membranes as a
result of changing concentration gradients) chemical redistribution. Cryo-
protectants (e.g. polyethylene glycol) can hinder ice crystal formation by
temporarily stabilising liquid H2O via hydrogen bonding. (b) Aldehydes and
oxidising agents diffuse across the cell membrane and covalently crosslink
lysine residues with an aliphatic bridge, disrupting tertiary protein structure
while also anchoring proteins to cell membranes. Proteins, phospholipids
and carbohydrates are partially lost to aldehyde fixation, and labile metals
undergo two-way exchange. (c) Alcohols and organic solvents rapidly
denature proteins to induce aggregation while simultaneously permeabilis-
ing membranes. This causes a loss of phospholipids and leaching of nucleic
acids into the cytosol. (d) Non-ionic surfactants (e.g. polysorbate-20, Triton
X-100) permeate bilipid membranes and allow antibodies to penetrate cells
and organelles, which undoubtedly causes some degree of chemical
redistribution. (e) Long-term archiving of biological samples at room tem-
perature requires protein stabilisation, dehydration, and substitution of H2O
with aliphatic hydrocarbons via formalin fixation and paraffin embedding
(FFPE). (f) Fixation and preservation may mask the target epitope, thus heat
or proteolytic (e.g. trypsin) cleavage of crosslinks, known as antigen retrieval,
may be necessary to expose antigens to the antibody paratope.
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where damage to cell ultrastructure is beyond the practical
image resolution obtained.
Aldehydes, oxidising agents, and organic solvents are the most
commonly-used chemical fixatives. Aldehydes and oxidants forms
covalent cross-links between amino acids, stabilising protein struc-
ture and anchoring proteins to cell membranes. Organic solvents
denature proteins and induce the formation of insoluble aggre-
gates. Fixation efficiency is determined by adequate penetration of
a cell; therefore, exposure time, sample thickness, and temperature
are variables that may produce inconsistencies. Organic solvents
have the advantage of simultaneously permeabilising the cell, while
aldehyde fixation is normally followed by immersion in a buffer
containing a non-ionic surfactant. By removing lipids from the
outer cell membrane antibodies are able to penetrate the cell,
though removing such barriers allows soluble chemicals to diffuse
beyond their native cellular compartment.
Hackett et al.17 applied a multimodal imaging approach using
both FTIR and PIXE imaging to assess effects of formalin fixation on
the native microchemistry of neurological tissue. Using cryofixed
and freeze-substituted tissue as a reference, FTIR spectra demon-
strated marked decreases in vibrational intensities assigned to
amides, olefinic carbon–hydrogen bonds, covalent carbon–oxygen
bonds, and phosphates, indicating loss of proteins, carbohydrates,
lipids, and lipid oxidation products. Even simple immersion in
phosphate buffered saline had measurable effects on organic con-
tent. Hobro and Smith18 capitalised on the ability of Raman
spectroscopy to image live cells to evaluate the effects of immersion
in aldehydes, organic solvents, and permeabilising surfactants. All
reagents produced measurable changes in Raman spectra indicative
of chemical redistribution and structural modification. This study is
particularly informative as it not only demonstrates the differential
effects of each reagent, but also how ambient conditions and order
of chemical exposure can be optimised to preserve a specific class of
biomolecule.
Unsurprisingly, both studies found that cytoplasmic proteins
are particularly susceptible to leaching and redistribution. The
same can also be said for labile and weakly-bound inorganics;
quantitative elemental mapping of formalin-fixed brain tissue
sections using PIXE showed near-total loss of intracellular
potassium and reduction in chlorine. Conversely, calcium and
the major biologically-relevant transition metals (iron, copper
and zinc) all showed increased concentrations within cells.
Similar observations were made by Chwiej et al.,19 who used
X-ray fluorescence spectroscopy to show differential influx and
efflux of biologically-relevant elements in various areas of rat
brain sections following formalin or paraformaldehyde fixation,
with paraffin-embedded counterparts showing a marked decrease
in nearly all measured elements. External contamination is clearly
a point of consideration; when high-purity reagents are used,
aldehyde fixation and sucrose cryoprotection resulted in loss of
most biologically-relevant metals.20 The degree of metal loss is not
uniform, and species-specific effects can be attributed to variable
affinities of metals to protein ligands, per the Irving–Williams
series:21
Mg2+ o Mn2+ o Fe2+ o Co2+ o Ni2+ o Cu2+ E Zn2+
Archived samples provide cost-effective access to a vast array of
disease states and tissue types, though stability during long-term
storage necessitates substantial chemical treatment. Samples
are fixed in formalin over several hours, dehydrated and cleared
in ethanol and xylene, then infiltrated with and embedded in
paraffin for indefinite storage at room temperature. A compre-
hensive review of ex vivo modifications to proteins, nucleic acids
and cell structure resulting from formalin-fixation and paraffin
embedding (FFPE) protocols is detail in Bass et al.22 Use of
archived FFPE tissue introduces several sources of analytical
uncertainty—initial fixation time, FFPE protocol and other pre-
treatments such as decalcification are not typically recorded and
likely vary between repositories. Immunoreactivity decreases
over time, though antigen decay is not uniform,23 meaning
comparisons should only be made between samples of a similar
age that underwent an identical FFPE protocol, and even then
observations are empirical.
Finally, cross-linked proteins often mask an antigenic site
and antigen retrieval may be necessary to expose sufficient
numbers of epitopes prior to antibody incubation. The two most
common methods used are: (i) heat-induced, where the sample
is incubated in buffers containing surfactants and EDTA at high
temperature and pressure; and (ii) protease-induced, where
protein cross-links are enzymatically cleaved. Both approaches
undoubtedly cause modifications to other biomolecules, and it is
fitting that the authors of the first heat-induced antigen retrieval
protocol commented on the need for standardisation in IHC,
particularly regarding chemical fixation.24 Over a quarter of a
century later, many of the cautions raised have still not been
addressed.
Chemical alterations to the sample during preparation for
IHC are ultimately unavoidable. Therefore, steps taken should
be sufficient to produce adequate (and equivalent) immuno-
staining using conditions that are both compatible with the
antibody used and have minimal effects on the native bio-
chemicals being analysed.
3.2.2 Optimising antibody concentration. Commercially-
available antibodies ship with comprehensive datasheets, sug-
gesting optimal experimental parameters based on the intended
application, including IHC staining of frozen and FFPE sections,
and detection method used (e.g. fluorescence, light or electron
microscopy). Most datasheets provide suggested concentrations
for routine optical microscopy. While recommended dilutions
may not be optimal for the analyte or chemical imaging tech-
nique used, preparing samples in parallel for fluorescence or
light microscopy provides a useful point of reference for further
method development and quality control.
Non-specific binding below the ordinary threshold of detec-
tion for routine microscopy may cause significant interference
when more sensitive chemical imaging modalities are used.
Conversely, higher antibody concentrations may be necessary
for detecting certain analytes. When a new antibody is being
tested, a titration experiment should be performed specific to
the detection method used where antibody concentration is the
only variable. This is also the ideal point to prepare an isotype
control, where the primary antibody is substituted with an
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otherwise-identical immunoglobulin raised against an antigen
not present in the sample to determine levels of non-specific
binding (Fig. 4). These should also be conducted in parallel
with conventional immunohistochemical detection by optical
microscopy.
3.2.3 Multiplexing. Several antigens can be visualised in a
single multiplexed IHC experiment. Multiplexed IHC ranges from
routine colocalisation studies of three analytes to high-powered
computational image analysis of over two dozen labelled
proteins. Multiplexing is highly relevant to chemical imaging
as it both demonstrates the capabilities of non-traditional
IHC imaging methods, and it provides new opportunities for
multivariate profiling of complex molecular pathways and cell
hierarchies.
Multiplexing is dependent on the ability of an imaging
technique to resolve signals from each chemical reporter. For
fluorescence microscopy, brightness and areal density of the
fluorophore determine intensity of emission. Peak broadening
proportional to fluorophore density can produce spectral overlap
and potential false-positive measurements. A typical fluorescence
IHC assay uses emission from three sources (e.g. two fluorophore-
labelled secondary antibodies and a dye such as 40,6-diamidino-
2-phenylindole [DAPI], that fluoresces when bound to a specific
structural marker, in this case DNA), though some commercial
autostainer and microscopy systems have been optimised for
up to seven specific fluorophores. Quantum dots (QDs) offer
several advantages over traditional fluorophores. Fluorescent
emission of QDs is proportional to size, with larger diameter
dots emitting into the near-IR region. QDs are resistant to
photobleaching and brighter than conventional fluorophores,
and surface chemistry can target specific ligands on whole
antibodies or antibody fragments, as well as single-chain variant
fragment fusion proteins. A detailed overview and protocol for
designing multiplexed IHC experiments with QDs can be found
in Xing et al.26
Even greater flexibility is provided by MS for imaging metal-
tagged antibodies, which shifts the limiting factor from spectral
overlap to the number of unique combinations of primary and
secondary antibody host species used for indirect detection
(Fig. 5a), or the number of antibodies to which unique photo-
cleavable mass tags can be conjugated for molecular mass
spectrometry (see below). The true power of elemental MS
imaging for multiplexed IHC is evident when applied to direct
detection, which is limited only by the number of separate
analytes that can be associated with each primary antibody
(Fig. 5b). This was demonstrated by Giesen et al.,27 who used
commercial MaxPars monoisotopic lanthanide tagging kits to
label and simultaneously image 32 antibodies at 1 mm resolution
(Fig. 5c) with a laser ablation system coupled to a CyTOF-MS (an
ICP-MS design optimised for mass cytometry). This particularly
elegant study not only demonstrated a near-five-fold improve-
ment on the maximum number of antigens that can be detected
using fluorescence microscopy; it also described an image pro-
cessing algorithm using lanthanide-labelled structural features to
segment and extract data from single cells which subsequently
underwent spanning-tree progression analysis of density-
normalised events (SPADE) to characterise tumour hetero-
geneity in breast cancer tissue microarrays. Designed for CyTOF
mass cytometry, SPADE examines multidimensional datasets to
characterise cell–cell interactions and transitions to construct
hierarchical trees of diverse cell populations, it has enormous
potential for examining spatial interactions between antigens
and associated endogenous chemicals. Angelo et al.28 used a
similar IHC protocol with nanoSIMS detection and their own
cell-segmentation algorithm to image 10 analytes at 200–300 nm
resolution, and used both signal intensity and categorical expres-
sion (i.e. positive or negative) to build composite images repre-
senting immunohistochemical and phenotypic features of
malignant cells (Fig. 5d). Both studies used classical light and
fluorescence microscopy to demonstrate specificity and sensi-
tivity (Fig. 5e and f). The LA-CyTOF-MS system originally
described by Giesen et al.27 was recently commercialised as
the Heliost by Fluidigm, from which the first applications are
now emerging.29 By design, the Heliost system is optimised for
high-mass lanthanide detection, thus simultaneous imaging of
biologically-relevant elements, most of which fall below the
Fig. 4 (a) Isotype control and titration experiment for a 173Yb-labelled sheep
anti-mouse tyrosine hydroxylase (TH) primary antibody-stained coronal
mouse brain section, imaged using LA-ICP-MS. 173Yb-labelled sheep IgG,
which should have no specific reactivity to mouse tissue, shows a uniform
pattern of non-specific binding slightly above background. Increasing anti-
body concentration increases background to a point where non-specific
binding decreases signal-to-noise to a point that obscures antigen-specific
analyte signal. (b) In situ hybridisation and gene expression maps from the
Allen Brain Atlas25 can be used as additional reference for wild-type protein
distribution; here, sections taken at the same anatomical coordinates shows
TH expression is mainly in the lower right quadrant of the brain hemisphere
containing the basal ganglia formation.
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80 amu threshold, is hardware-limited. New ICP-TOF-MS systems
capable of concurrently measuring both low- and high-mass
elements, such as the TOFWERK design, will eventually be used
for correlative LA-ICP-MS imaging of multiplexed IHC with
endogenous metals and heteroatoms.
Photocleavable mass tags can be used in a similar approach
for multiplexed IHC experiments using molecular MS imaging,
allowing detection of intact proteins normally outside the mass
range of TOF mass analysers. Here, the analyte consists of a
molecule or peptide with a known mass linked to the antibody
via an organic linker (either directly or as part of an avidin–
biotin complex) with a photo-sensitive region that releases the
mass tag when exposed a specific wavelength, normally that of
the MALDI ionisation source. By not applying a matrix prior to
analysis, signal-to-noise ratios for the applied mass tags allow
for highly sensitive targeted multiplexed detection using both
primary antibodies30 and enzyme activity probes.31 Subsequent
matrix application and traditional MALDI-MS imaging can then
be used to examine spatial associations between mass-tagged
antigens and endogenous biomolecules.
Most examples of IHC-chemical imaging using vibrational
spectroscopy take advantage of stimulated Raman scattering,
which produces vibrational transitions around 150 times
narrower than fluorescence emission spectra. Wei et al.32 synthe-
sised a panel of 14 p-conjugated CRC or CRN-containing dyes
with isotopic 13C and 15N substitution to supplement six com-
mercial Raman-scattering dyes and four fluorophores to simulta-
neously resolve 24 analytes in multiplexed IHC-stained cultured
cells and tissue sections. Functionalisation of antibodies with
materials such as gold and silver nanomaterials can be used with
surface enhanced Raman scattering (SERS) and surface plasmon
resonance spectroscopy for multiplexed imaging, where the size
and shape of conjugated particles can be manipulated to pro-
duce a unique, resolvable signal.33
3.3 Validating IHC-chemical imaging experiments
To date, most applications of IHC using chemical imaging have
been proof-of-concept and focused primarily on the analytical
technique used, as opposed to the full suite of analytical validation
steps that would ordinarily be taken for more routine experi-
ments where a known target is isolated, identified, and quantified.
Fitzgibbons et al.’s Principles of Analytic Validation of Immunohis-
tochemical Assays11 is required reading when developing any IHC-
based chemical imaging experiment. Although the 14 guideline
statements are geared toward eventual FDA approval of a new IHC
method, they are conceptually analogous to standard validation
steps common to analytical chemistry. When setting the rubric, the
CAP approached the issue with the overarching question of ‘‘[w]hat
is needed for initial analytic assay validation before placing any IHC
test into clinical service and what are the revalidation require-
ments?’’.11 Rather than dissect the 14 guideline statements, we will
examine the five scope questions on which Fitzgibbons et al. based
their recommendations, and use a hypothetical experiment
studying copper metabolism in the mouse brain using LA-ICP-MS
(Fig. 6a) to illustrate how analytical validation can be applied to any
research-based IHC chemical imaging scenario.
Fig. 5 Multiplexed IHC using fluorescence microscopy and MS imaging.
(a) Simplified conceptual schematic of quintuplexed IHC using four
secondary antibodies and a DNA-specific probe. Primary antibodies for
human antigens raised in four different species are indirectly detected by
secondary antibodies with conjugated fluorophores. Resolving signal
associated with each antigen requires complex optics and fluorophore
emission spectra with minimal overlap. An alternative to overcome spectral
overlap uses secondary antibodies labelled with monoisotopic lanthanides
(coloured here to match fluorescent tags) and an iridium-containing
DNA intercalator, followed by MS imaging. (b) Direct detection of primary
antibodies capitalising on the resolving power of MS can be used to
substantially increase the number of target antigens. (c) Three-colour
LA-CyTOF-MS image of 174Yb-tagged cytokeratin 8/18 (red), 176Yb-
tagged H3 (cyan) and 162Dy-tagged vimentin (yellow) from a 32-plexed
human breast cancer tissue microarray.27 (d) Composite nanoSIMS image
of mass intensities for cytoplasmic 168Er-tagged actin (red), 158Gd-tagged
E-cadherin (green) and 154Sm-tagged vimentin (blue) with nuclei categori-
cally classified as either 139La-ERa + 145Nd-PR positive (aqua) or 139La-ERa +
145Nd-PR + 150Nd-Ki67 positive (yellow).28 (e) Addition of lanthanide tags to
primary antibodies (151Eu-tagged HER2 [red] and 176Yb-tagged H3 [cyan])
does not affect binding of fluorophore-conjugated secondary antibodies,
and (f) MS imaging reproduces immunofluorescence specificity.27 Panels (c),
(e) and (f) reproduced with permission from Giesen et al.;27 panel (d)
reproduced with permission from Angelo et al.28 (both Nature Publishing
Group, Copyright 2014).
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3.3.1 When and how should validation assess analytic[al]
sensitivity, analytic[al] specificity, accuracy (assay concordance),
and precision (interrun and interoperator variability)? The devel-
opment of a new IHC-chemical imaging method should aim to
design, conduct, analyse, interpret, and report protocols in a way
that can be independently replicated. In their systematic review
of literature conducted to set guidelines for IHC validation,
Fitzgibbons et al. found only 126 of a total 1463 extracted studies
(8.6%) met inclusion criteria,11 highlighting the lack of con-
sensus regarding an appropriate approach to confirm IHC assay
validity.
In our hypothetical experiment, a multiplexed approach
using lanthanide-tagged secondary antibodies was developed
and applied to image two major copper regulatory proteins,
copper transporter-1 (Ctr1) and metallothionein (MT) in sections
from fresh-frozen, paraformaldehyde-fixed wild-type and transgenic
murine brains using modified IHC protocols, while simultaneously
monitoring how regional copper levels are affected by ablation and
overexpression of either protein (Fig. 6b). The animals used were
the wild-type background strain (hereafter WT), heterozygous Ctr1
mice (Ctr1KO)34 and a hypothetical overexpressor (Ctr1Tg; over-
expression of Ctr1 and resulting copper accumulation has been
demonstrated in vivo34), combined MT1/2-null (MT1/2KO) and
transgenic overexpressors (MT1/2Tg).35 Analytical sensitivity
and specificity were assessed from the outset using antibody
titrations and isotype controls to experimentally determine the
optimal antibody concentrations.
Two questions regarding specificity can be raised. Firstly,
can MT1 be distinguished from MT2, and could cross-reactivity
with MT3 produce false-positive data? Most commercial anti-
bodies target N-terminus epitopes in the b-domain that share
100% homology between MT1 and 2; differentiation of MT1
and 2 would require raising monocloncal antibodies specific to
one isoform and confirmation by ELISA.36 Within the context of
Fig. 6 Hypothetical experimental design and validation using IHC-chemical imaging. (a) Two major regulators of cellular copper homeostasis are
the intramembrane protein copper transporter 1 (Ctr1) and cytosolic metallothionein (MT) family, of which MT1 and 2 isoforms are most abundant.
Knock-out (KO) of Ctr1 decreases cellular concentration, whereas transgenic overexpression (Tg) increases copper content. The aim of this hypothetical
experiment is to compare Ctr1 modulation with MT1/2 KO and Tg mice with respect to brain copper concentration and distribution. (b) Ctr1 and MT1/2
are detected using modified IHC protocols with lanthanide-tagged secondary antibodies, and distribution of lanthanides and endogenous copper
imaging using LA-ICP-MS. (c) Several routine techniques including standard IHC with light microscopy detection, use of reference in situ hybridisation
databases,25 total tissue copper assay by ICP-MS, and western blotting for relative protein concentration are used to determine accuracy, precision and
sample size. (d) When applied to a fully developed IHC-LA-ICP-MS method, spatial copper distribution in the brain can be compared and contrasted with
wild type and Ctr1 KO/Tg animal.


























































































This journal is©The Royal Society of Chemistry 2018 Chem. Soc. Rev., 2018, 47, 3770--3787 | 3783
this experiment, where MT1 and 2 perform an equivalent
function and manipulation of protein expression was universal,
differentiation of isoforms was not considered necessary.
Regarding MT3, the b-domain epitope shares only three com-
mon residues and cross-reactivity is absent36—this could be
experimentally demonstrated by the presence of MT3 staining
in MT1/2KO animals.
The second is whether MT and non-MT copper can be
distinguished. In this case, only spatial association between
MT1/2 and copper can be inferred from LA-ICP-MS images as
the analyte marking MT1/2 spatial distribution is indicative of
the protein only, whereas copper images represent all chemical
forms in the sample. Thus, appraising the direct relationship
between MT1/2 and associated copper levels would require
additional biochemical analysis and subsequent loss of spatial
information.
Determining accuracy and precision requires a reference
standard against which chemical images can be compared
(Fig. 6c). Where a relatively low spatial resolution is being used
comparisons against light microscopy images may be suffi-
cient, though using a non-IHC assay (i.e. in situ hybridisation
in either the source material11 or from open-access databases25)
increases confidence. The proportional response to concentration
adds an additional dimension when assessing precision. Inter-
experiment and inter-operator precision is assessed as reproduci-
ble localisation of tagged Ctr1 and MT1/2, and a consistent signal
intensity in repeated measures of WT animals where relative
protein expression levels have been externally confirmed (i.e. by
western blot). A minimum concordance rate of 90% is the
recommended standard for IHC.11
3.3.2 What is the minimum number of positive and nega-
tive cases that need to be tested to analytically validate an IHC
assay for its intended use(s)? The expert consensus opinion of
Fitzgibbons et al.11 states that non-predictive factors should be
validated using 10 positive and 10 negative cases (in this case
WT vs. Tg overexpressors and/or KO animals), increasing to 20 for
predictive marker (factors with a confirmed association to treat-
ment response or resistance) assays. In our example, copper
levels should also be considered; heterozygous Ctr1-null mice
(homozygotes display embryonic lethality) exhibit a 50% decrease
in total brain copper levels.34 With such a substantial difference
between WT and Ctr1KO animals, a statistical power calculation
would suffice with o10 animals per group, though for MT1/2KO
mice where effects on brain copper levels are more subtle,35 a
larger experimental population may be required. Power calcula-
tions based on quantitative measurement of total copper, Ctr1,
and MT1/2 protein expression aid in determining the sufficient
number of cases for validation.
3.3.3 What parameters should be specified for the tissues
used in the validation set? The aim of the hypothetical imaging
experiment described was to determine how altering two major
copper regulatory proteins influenced regional copper levels and
spatial associations. Therefore, the validation set is the experi-
mental group against which others are to be compared. As for
any IHC experiment, all possible confounding parameters
should be controlled for, beginning with sample collection and
ending with how data is analysed. All samples should undergo
identical preparations steps, use single-origin reagents and
antibodies, and be analysed using the same LA-ICP-MS system.
3.3.4 How do certain preanalytic variables influence analytic
validation? Controlling preanalytic variables for IHC-chemical
imaging in a research setting such as the example described is
relatively simple: animals are sourced from the same background
genetic strain, housed in the same conditions (light/dark cycle;
water and food from the same source), and tissue prepared using
a standard protocol. However, even with consistency across
sample preparation methods, there may be differential effects
on certain analytical targets. For instance, Ctr1 overexpression
may increase cellular copper levels to a point where microchem-
ical equilibria is disrupted so much as to increase labile copper,
which is disproportionately lost during fixation and staining,
compared to WT where labile copper is essentially absent and
protein-copper ligands are resistant to chemical perturbations.
While there is no gold standard of native metal spatial distribu-
tion against which it can be compared,37 external measurement
of total copper levels in unadulterated tissue, as well as quanti-
tative measurement of copper levels in tissue prior to and after
each processing step could be employed to either confirm metal
levels are unaffected, or determine the degree of change and
whether it is consistent across multiple samples. This can be
achieved using LA-ICP-MS imaging, or by independent methods
including autoradiography or histochemical stains (reviewed by
McRae et al.6), although in the latter case it should be acknowl-
edged that harsh chemical conditions may perturb native
distribution, sensitivity is substantially lower than MS imaging,
and precipitation with other endogenous metals may produce
false-positives.
3.3.5 What conditions require assay revalidation? With all
variables controlled and appropriate sample numbers analysed,
our hypothetical experiment has reached a point where analy-
tically valid comparisons between groups can be made (Fig. 6d).
Further experiments can be carried out using the same experi-
mental conditions, though several scenarios would require
some degree of revalidation. Adapting the recommendations
by Fitzgibbons et al.,11 new reagents should be tested with one
negative and positive control, and minor modifications to the
protocol such as incubation time, antibody dilution and batch
(assuming the same clone), should be confirmed with two
negative and positive control cases. Additional factors to con-
sider include variable antibody-analyte labelling and detection
efficiencies between analytical systems. For lanthanide tagging
and mass cytometry, Tricot et al.38 identified areas where
method standardisation and data normalisation are necessary
for interlaboratory harmonisation, all of which are directly
relevant to MS imaging and conceptually applicable to other
chemical imaging modalities.
4. Opportunities and future challenges
Potential applications for IHC-chemical imaging are vast and
varied, and primarily depend on two variables: the chemical
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nature of the analyte serving as a fiducial proxy for the antigen
of interest; and other biomolecules with which they are asso-
ciated, which may be either endogenous or labelled with differ-
ent chemical reporter. In the following section, we provide a
brief summary of where IHC-chemical imaging can provide new
insight into functional biochemistry and discuss the challenges
that will arise as the field continues to evolve.
4.1 Multimodal imaging
Multimodal imaging describes the use of different detection
techniques used in sequence (asynchronous) or simultaneous
collection of signals from multiple analyte classes (synchronous).
Both approaches have inherent technical challenges; asynchro-
nous imaging requires registration of sequential images using
appropriate fiducial markers, while synchronous imaging often
involves complex, multistep sample preparation. Asynchronous
imaging should ideally have similar spatial resolution. As an
example on the extreme end, super resolution microscopy can
achieve spatial resolutions at or below the spatial dimensions of a
typical IgG molecule, and identification of a biomolecule is
typically achieved through recognition of a specific peptide or
amino acid sequence by a small molecule fluorophore attached
by either direct conjugation or enzymatic delivery.39 When
coupled with electron microscopy and a common detectable
analyte, such as fluorescent tetramethylrhodamine which
mediates photooxidation and induces polymerisation of DAB,
correlative multimodal images of genetically-encoded tetra-
methylrhodamine-sensitive proteins and cell ultrastructure
can be generated.40
Que et al.41 applied a particularly innovative asynchronous
multimodal approach using a Zn2+-sensitive fluorescent sensor
and live-cell imaging (Fig. 7a) with subsequent scanning trans-
mission electron microscopy with energy-dispersive spectroscopy,
and synchrotron-based XFM and three-dimensional elemental
tomography to characterise zinc flux during oocyte maturation.
This method demonstrated that multimodal imaging need not
necessarily be performed on the same sample; information
gleaned from one technique was built upon by unique cap-
abilities of following imaging modalities to quantitatively asses
how ‘zinc sparks’ necessary for transition from egg-to-embryo
form and change subcellular compartmentalisation.
Capabilities of diffraction-limited fluorescence microscopy
are constantly being expanded by application of fluorophores
with greater quantum yields, and the development of novel
fluorescent sensors for endogenous chemicals, recently reviewed
by Kolanowski et al.43 Synchronous fluorescence microscopy
combining IHC with inducible fluorescence in transfected cell
lines, organelle markers, and small molecule sensors have
produced subcellular images with remarkable levels of detail
(Fig. 7b).
4.2 Small molecule sensors and temporal imaging
Over the last several decades a catalogue of cell-permeable and
highly-specific compounds that fluoresce in the presence of small
molecules have become commercially available, and the syn-
thesis of novel chemical sensors is a vibrant field of research.44
Fig. 7 Asynchronous and synchronous multimodal imaging (a) sequential
fluorescence imaging of ‘zinc sparks’ in maturing mammalian oocytes.
Murine cells at five distinct stages of meiosis were labelled with the Zn2+
sensor ZincBY-1 (green) and counterstained with a DNA-binding fluoro-
phore (blue). Oocytes were then fixed with paraformaldehyde and stained
with fluorescent Lens culinaris agglutinin (LCA; red) and nucleic acid-
marker DAPI (blue). LCA selectively binds to lectins on the surface of
cortical granules, and the similar pattern of ZincBY-1 fluorescence sug-
gests these vesicles are laden with Zn2+. Combined with XFM imaging, this
method was able to quantify the total zinc content of a single oocyte
(6  1010 atoms). Reproduced with permission from Que et al. (Nature
Publishing Group, Copyright 2014).41 (b) Merged (top) and false-colour
(bottom panels) images of parallel microscopy of HeLa cell structural
features using five distinct fluorescent analytes: (i) bisbenzimide (Hoechst
33342) binding to adenine–thymine-rich DNA minor grooves; (ii) transfec-
tion and expression of green fluorescent protein (GFP) bound to a-tubulin
via a six-amino acid linker; (iii) secondary antibodies with quantum dot
conjugates; (iv) 40,50-bis(arsenoso)resorufin (ReAsH) binding to mutant
b-actin containing a tetracysteine (Cys-Cys-Pro-Gly-Cys-Cys) motif; and
(v) traditional ICH with a Cy5–streptavadin–biotin fluorophore bound to
the Fab region of a secondary IgG antibody. Reproduced with permission
from Giepmans et al. (American Association for the Advancement of Science,
Copyright 2006).42
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Fluorophores specific to by-products of cellular respiration (such
as reactive nitrogen, oxygen, and sulfur species) at nanomolar
levels have provided new insight into cellular redox state and
subcellular effects of oxidative stress, and can be multiplexed to
spatially profile biochemical interactions.43 Specificity to a parti-
cular redox state permits snapshots of dynamic biochemical
equilibria, and reversible probes with stable quantum yields over
multiple redox cycles can be used to temporally profile changes to
cellular oxidative state as a result of normal cellular function or
chemical stimuli used as a disease mimetic. While these probes
can theoretically be coupled with antibody-conjugated fluoro-
phores in permeabilised cells, unavoidable perturbations to
native cellular redox state arising from IHC protocols limits
applications in live cell imaging.
4.3 Intact systems
Several methods for optical clearing, such as 3DISCO and
CLARITY, are allowing interrogation of structural and molecular
networks in intact biological systems using three-dimensional
microscopy such as confocal and light-sheet methods. CLARITY
is particularly appealing as impregnation of tissue with a fixative
and hydrogel monomer forms a polymerised ‘mesh’ support to
which proteins are bound.45 Addition of sodium dodecyl sulfate
then allows electrophoretic clearing of optically-opaque lipids,
leaving a transparent sample amenable to repeated IHC staining,
imaging, and antibody clearing using a detergent. Sequential
staining cycles produce diminishing returns, as approximately
8% of hydrogel-anchored proteins are lost during each surfac-
tant clearing step. The ideal scenario for CLARITY would be
single clearing step followed by multiplexed IHC with several
fluorophores covering a pre-determined panel of target bio-
molecules. Superior optical properties of QDs would appear to
be best suited, though QD-conjugated antibodies are unable to
match traditional fluorophores with respect to tissue penetra-
tion depth. Nevertheless, CLARITY and associated methods are
relatively new tools that will undoubtedly improve over the
coming years.
4.4 In situ quantification
Traditional IHC assesses sensitivity and quantification in a some-
what arbitrary and subjective manner based on visual inspection
of sections using light microscopy. A pathologist may assign a
binary positive/negative score with reference to a positive control,
use a narrow numerical range to rank staining intensity (i.e. 1–4),
or apply other grading systems that assess both staining intensity
and percentage of positive cells (e.g. H-scoring, quick scoring or
the Allred method46). Each method is manual, prone to inter-
observer bias, and chromogen development is difficult to stan-
dardise. Recent advances in digital image analysis, such as the
IHC Profiler plugin for ImageJ automate spectral deconvolution of
3,30-diaminobenzidine (DAB)-enhanced IHC-labelled cancer biop-
sies to segment and score staining intensity on a pixel-by-pixel
basis, reducing observer bias,47 though the resultant 8-bit colour
image is still used to stratify data according to four-point grading.
The availability of more comprehensive image analysis algorithms
for ImageJ, such as those in the Fiji (Fiji Is Just ImageJ) package,48
have dramatically expanded the capabilities of this public-domain
resource, and are applicable to all imaging modalities. Addition-
ally, by making algorithms used for cell segmentation and data
analysis, such as that used by Giesen et al.,27 publicly accessible
and in either open-access or commonly-used proprietary program-
ing languages, templates for custom-designed image analysis
software suited to the method used are available.
Absolute quantification of an antigen using chemical imaging
is, at least in theory, achievable, though considering the multiple
variables in existing IHC protocols that necessitate re-validation
it is unlikely that reproducible in situ quantification would ever
become mainstream. The ‘antibody binding capacity’, or ABC,
of a sample can be determined according to the following:49
ABC = n1y1l1 (1)
where n1 represents the number of antigen-binding sites, y1 is
the fraction of antigens to which a primary antibody is bound,
and l1 is the valence of the primary antibody (i.e. l1 = 0.5 for a
primary antibody where both paratopes recognise antigens on
two molecules). Two factors further contribute to the ABC of a
cell: steric hindrance of the epitope and non-specific binding.
McCloskey et al.50 extended the ABC concept to determine C,
which uses the same parameters to quantify recognition of the
primary antibody by indirect detection:
C = n2y2l2 (2)
Thus, if such an approach were to be applied to IHC-chemical
imaging, foreknowledge of antigen–antibody binding charac-
teristics, which vary substantially between batches and clones,
would be needed. Additionally, the number of antigen binding
sites (n) would have to be determined by an external method,
such as quantitative liquid chromatography-MS/MS for each
sample, after which the value of spatially assessing concen-
tration may become moot. External calibration could be applied,
where known concentrations of the target antigen are deposited
on a suitable substrate and undergo IHC preparation in parallel,
though this depends on: (i) the availability of purified protein
standards; (ii) complete characterisation of antibody binding
efficiency to give y and l; and (iii) confidence that the substrate
on which the standard is deposited is equivalent to the sample.
This latter point presents the biggest challenge; the factors
influencing y are all related to the presence of the antigen in a
complex cellular environment, one which cannot be easily
replicated using standard reference materials. There is no doubt
that novel methods for in situ quantification will be developed in
the future, though these will likely be application-specific, and
current methods were relative comparisons or categorical classi-
fications are used will continue to prevail.
5. Conclusions
Integrating IHC with chemical imaging represents the forefront
of transdisciplinary chemistry. As outlined in this Tutorial
Review, designing, executing, and validating an imaging experi-
ment using antibodies and novel analytes requires knowledge
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spanning the fundamental principles of IHC to the technical
intricacies of advanced analytical methods. However, with a
sound and methodical approach to conducting IHC-chemical
imaging experiments, the potential insight into complex bio-
chemical processes that stands to be gained is, metaphorically
speaking, almost immeasurable.
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